#ESCCongress – [Abstract Only] Randomized trial: Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome

Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial – The Lancet

Commentary: Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial – Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients – HOST-REDUCE-POLYTECH-ACS – American College of Cardiology

Commentary on Twitter

Late breaking at #ESCCongress—Prasugrel-based de-escalation of dual antiplatelet therapy after PCI in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial https://t.co/yvcdB4rZ9x pic.twitter.com/GhPfztHwMX

— The Lancet (@TheLancet) August 31, 2020